NEW YORK, March 13, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Kitov Pharmaceutical Holdings Ltd. securities (NASDAQ:KTOV) pursuant and/or traceable to Kitov’s initial public offering on or about November 20, 2015 (the “IPO”) and/or on the open market from November 20, 2015 through February 3, 2017, both dates inclusive (the “Class Period”) of the important April 10, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Kitov investors under the federal securities laws.
To join the Kitov class action, go to http://www.rosenlegal.com/cases-1051.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Kitov and its CEO Isaac Israel published misleading information concerning the conduct of Kitov’s clinical trials for its lead drug candidate KIT-302; and (2) as a result, Kitov’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 10, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1051.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 



